Logo image of SERA

SERA PROGNOSTICS INC-A (SERA) Stock Overview

USA - NASDAQ:SERA - US81749D1072 - Common Stock

3.65 USD
+0.3 (+8.96%)
Last: 10/24/2025, 4:30:01 PM

SERA Key Statistics, Chart & Performance

Key Statistics
Market Cap138.92M
Revenue(TTM)108.00K
Net Income(TTM)-32731000
Shares38.06M
Float32.89M
52 Week High9.13
52 Week Low1.37
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.85
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/amc
IPO2021-07-15
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


SERA short term performance overview.The bars show the price performance of SERA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15

SERA long term performance overview.The bars show the price performance of SERA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100

The current stock price of SERA is 3.65 USD. In the past month the price increased by 18.12%. In the past year, price decreased by -47.56%.

SERA PROGNOSTICS INC-A / SERA Daily stock chart

SERA Latest News, Press Relases and Analysis

SERA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.53 402.76B
AMGN AMGEN INC 13.38 157.07B
GILD GILEAD SCIENCES INC 15.63 150.06B
VRTX VERTEX PHARMACEUTICALS INC 24.88 108.04B
REGN REGENERON PHARMACEUTICALS 12.66 61.26B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.75B
ARGX ARGENX SE - ADR 88.74 50.32B
ONC BEONE MEDICINES LTD-ADR 5.02 34.14B
INSM INSMED INC N/A 33.75B
NTRA NATERA INC N/A 26.42B
BNTX BIONTECH SE-ADR N/A 25.40B
BIIB BIOGEN INC 9.36 21.98B

About SERA

Company Profile

SERA logo image Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.

Company Info

SERA PROGNOSTICS INC-A

2749 E. Parleys Way, Suite 200

Salt Lake City UTAH US

CEO: Gregory C. Critchfield

Employees: 64

SERA Company Website

SERA Investor Relations

Phone: 18015050278

SERA PROGNOSTICS INC-A / SERA FAQ

What does SERA do?

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 63 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.


Can you provide the latest stock price for SERA PROGNOSTICS INC-A?

The current stock price of SERA is 3.65 USD. The price increased by 8.96% in the last trading session.


What is the dividend status of SERA PROGNOSTICS INC-A?

SERA does not pay a dividend.


What is the ChartMill technical and fundamental rating of SERA stock?

SERA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the sector and industry classification for SERA PROGNOSTICS INC-A?

SERA PROGNOSTICS INC-A (SERA) operates in the Health Care sector and the Biotechnology industry.


How is the valuation of SERA PROGNOSTICS INC-A (SERA) based on its PE ratio?

SERA PROGNOSTICS INC-A (SERA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).


What is SERA PROGNOSTICS INC-A worth?

SERA PROGNOSTICS INC-A (SERA) has a market capitalization of 138.92M USD. This makes SERA a Micro Cap stock.


SERA Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to SERA. When comparing the yearly performance of all stocks, SERA is a bad performer in the overall market: 86.45% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SERA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SERA. The financial health of SERA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SERA Financial Highlights

Over the last trailing twelve months SERA reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS increased by 13.27% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -29.27%
ROE -37.1%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%36%
Sales Q2Q%-29.17%
EPS 1Y (TTM)13.27%
Revenue 1Y (TTM)2.86%

SERA Forecast & Estimates

For the next year, analysts expect an EPS growth of 21.7% and a revenue growth 118.18% for SERA


Analysts
Analysts85
Price TargetN/A
EPS Next Y21.7%
Revenue Next Year118.18%

SERA Ownership

Ownership
Inst Owners64.87%
Ins Owners2.66%
Short Float %1.93%
Short Ratio6.55